Ebola virus vaccine - Crucell/Vaccine Research Center

Drug Profile

Ebola virus vaccine - Crucell/Vaccine Research Center

Alternative Names: VRC-EBOADV018-00-VP

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaccine Research Center
  • Developer Crucell; Vaccine Research Center
  • Class Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Ebola virus infections

Most Recent Events

  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 28 Feb 2008 Phase I development is ongoing
  • 26 Sep 2006 Phase-I clinical trials in Ebola virus infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top